Richter partner drug approved in Canada
Image by LaMography/Moni Lazar
Hungarian pharmaceutical company Gedeon Richter yesterday said its partner AbbVie announced the approval of the antipsychotic Cariprazine, sold under the brand Vraylar, by Canada's drug authority, according to a release on the website of the Budapest Stock Exchange.
Health Canada approved Vraylar as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar I disorder in adults, as well as treatment of schizophrenia in adults, Richter said.
Cariprazine, also sold under the brand Reagila, was Richter's top-selling product last year, generating a turnover of close to HUF 107 billion.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.